

7 November 2024

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Conversion of Convertible Loan Notes**

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, announces it has received notices to convert a total face value of £267,106 convertible loan notes (the "CLNs") resulting in the issue of 6,586,604 new ordinary shares in the Company (the "CLN Shares").

In accordance with the terms of the CLNs, which were issued on 23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is included in the conversion into the Company's ordinary shares of £0.01 each ("Ordinary Shares"). The conversion price of the CLNs is 4.29p, being 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date, which is three business days prior to the notice of conversion given to the Company.

Following conversion of these CLNs, the Company has CLNs with a face value of £387,894 outstanding.

**Director/PDMR Shareholding**

The abovementioned notices to convert included notices from directors Stephen West, Ajan Reginald and Darrin Disley, as follows:

<b>Director</b>	<b>CLN Face Value</b>	<b>CLN Shares</b>	<b>Total Ordinary Shares Held After CLN Shares Issued</b>
Stephen West	£28,158	694,352	6,310,853
Ajan Reginald	£26,316	648,930	12,311,981
Darrin Disley	£21,053	519,149	2,015,050

**Admission and Total Voting Rights**

Application will be made for the CLN Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 12 November 2024 ("Admission"). The CLN Shares will rank *pari passu* in all respects with the Company's existing Ordinary Shares.

Following Admission, the Company's issued share capital will comprise 135,736,602 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 135,736,602 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

### **Regulatory Information**

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

### **ENDS**

#### **Enquiries:**

<b>Roquefort Therapeutics plc</b>	+44 (0)20 3918 8633
Stephen West (Chairman) / Ajan Reginald (CEO)	
<b>SP Angel Corporate Finance LLP (Broker)</b>	+44 (0) 20 3470 0470
David Hignell / Vadim Alexandre / Devik Mehta	
<b>Buchanan (Public Relations)</b>	+44 (0)20 7466 5000
Ben Romney / Jamie Hooper / George Beale	
<b>Peak IR (Investor Relations)</b>	+33 (0)7 44 44 15 42
Seb Wykeham	

LEI: 254900P4SISIWOR9RH34

### **About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunology and oncology markets prior to partnering with big pharma.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;

- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK cell-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on X (formerly Twitter).

**The notification below, made in accordance with the requirements of the UK MAR, provides further detail:**

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

**1 Details of the person discharging managerial responsibilities / person closely associated**

a) Name Stephen West

**2 Reason for the notification**

a) Position/status Executive Chairman

b) Initial notification /Amendment Initial

**3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**

a) Name Roquefort Therapeutics plc

b) LEI 254900P4SISIWOR9RH34

**4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**

a) Description of the financial instrument, type of instrument Ordinary shares of £0.01 par value

Identification code ISIN: GB00BMDQ2T15

b) Nature of the transaction Conversion of loan notes into 694,352 ordinary shares

c) Price(s) and volume(s) Price(s) Volume(s)

4.29 pence per share 694,352

d) Aggregated information

- Aggregated volume - 694,352

- Price - 4.29p

e) Date of the transactions 7 November 2024

f) Place of the transactions London Stock Exchange (XLON); Main Market

**The notification below, made in accordance with the requirements of the UK MAR, provides further detail:**

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

**1 Details of the person discharging managerial responsibilities / person closely associated**

a) Name Ajan Reginald

**2 Reason for the notification**

a) Position/status Chief Executive Officer

b) Initial notification /Amendment Initial

**3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**

a) Name Roquefort Therapeutics plc

b) LEI 254900P4SISIWOR9RH34

**4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**

a) Description of the financial instrument, type of instrument Ordinary shares of £0.01 par value

Identification code ISIN: GB00BMDQ2T15

b) Nature of the transaction Conversion of loan notes into 648,930 ordinary shares

c) Price(s) and volume(s) Price(s) Volume(s)

4.29 pence per share 648,930

d Aggregated information

- Aggregated volume - 648,930

- Price - 4.29p

e) Date of the transactions 7 November 2024

f) Place of the transactions London Stock Exchange (XLON); Main Market

**The notification below, made in accordance with the requirements of the UK MAR, provides further detail:**

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

**1 Details of the person discharging managerial responsibilities / person closely associated**

a) Name Dr Darrin Disley

**2 Reason for the notification**

a) Position/status Non-Executive Director

b) Initial notification /Amendment Initial

**3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**

a) Name Roquefort Therapeutics plc

b) LEI 254900P4SISIWOR9RH34

**4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**

a) Description of the financial instrument, type of instrument Ordinary shares of £0.01 par value

Identification code ISIN: GB00BMDQ2T15

b) Nature of the transaction Conversion of loan notes into 519,149 ordinary shares

c) Price(s) and volume(s) Price(s) Volume(s)

4.29 pence per share 519,149

d Aggregated information

- Aggregated volume - 519,149

- Price - 4.29p

e) Date of the transactions 7 November 2024

f) Place of the transactions London Stock Exchange (XLON); Main Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CONBIBDBIGGDGSL

Anonymous (not verified)

Conversion of Convertible Loan Notes

<http://www.DigitalLook.com>

34674501

A

Thu, 11/07/2024 - 07:00

LSE RNS

Company Announcement - General

ROQ